| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA2371267
Max Phase: Preclinical
Molecular Formula: C11H19N3O4
Molecular Weight: 257.29
Molecule Type: Protein
Associated Items:
Representations
Canonical SMILES: C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O
Standard InChI: InChI=1S/C11H19N3O4/c1-6(12)10(16)14-5-3-4-8(14)9(15)13-7(2)11(17)18/h6-8H,3-5,12H2,1-2H3,(H,13,15)(H,17,18)/t6-,7-,8-/m0/s1
Standard InChI Key: IPZQNYYAYVRKKK-FXQIFTODSA-N
Associated Targets(non-human)
Tripeptidyl aminopeptidase 141 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 257.29 | Molecular Weight (Monoisotopic): 257.1376 | AlogP: -1.09 | #Rotatable Bonds: 4 |
| Polar Surface Area: 112.73 | Molecular Species: ACID | HBA: 4 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 3.65 | CX Basic pKa: 8.08 | CX LogP: -3.64 | CX LogD: -3.72 |
| Aromatic Rings: 0 | Heavy Atoms: 18 | QED Weighted: 0.59 | Np Likeness Score: -0.66 |
References
| 1. Ganellin CR, Bishop PB, Bambal RB, Chan SM, Law JK, Marabout B, Luthra PM, Moore AN, Peschard O, Bourgeat P, Rose C, Vargas F, Schwartz JC.. (2000) Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: a strategy for the design of peptidase inhibitors., 43 (4): [PMID:10691692] [10.1021/jm990226g] |
Source
Source(1):